Barclays analyst Carter Gould raised the firm’s price target on Amgen to $315 from $300 and keeps an Equal Weight rating on the shares as part of an earnings preview for the biopharmaceutical group. The firm sees a challenging large-cap biopharma setup for Q3.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Piper Sandler biotech analysts hold an analyst/industry conference call
- Amgen partners with La La Anthony
- Wynn Resorts upgraded, HP Inc. downgraded: Wall Street’s top analyst calls
- Amgen initiated with an Overweight at Cantor Fitzgerald
- Viridian Therapeutics price target raised to $61 from $56 at BTIG